

May 31, 2023

<p>To</p> <p>The Corporate Relations Department BSE Limited Phiroz Jeejeebhoy Towers, 25th Floor, Dalal Street Mumbai – 400001</p> <p>Code: 540222</p>	<p>To</p> <p>The Listing Department National Stock Exchange of India Limited Exchange Plaza, Bandra Kurla Complex, Bandra (East) Mumbai – 400 051</p> <p>Code: LAURUSLABS</p>
------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Dear Sirs,

Sub: **Press Release titled – “Laurus Labs further invests in Cell and Gene therapy company ImmunoACT; to hold 33.86% stake post- completion of the transaction”.**

Please find enclosed the Press Release titled - “Laurus Labs further invests in Cell and Gene therapy company ImmunoACT; to hold 33.86% stake post- completion of the transaction”.

This is for your information and records.

Thanking you,

Yours sincerely,
For Laurus Labs Limited

G. Venkateswar Reddy
Company Secretary

Encl: As above

Laurus Labs further invests in Cell and Gene therapy company ImmunoACT; to hold 33.86% stake post-completion of the transaction

Hyderabad, May 31, 2023: Laurus Labs Ltd. (Laurus BSE: 540222, NSE: LAURUSLABS, ISIN: INE947Q01028)

Laurus Labs announced today that it has signed definitive agreements to acquire additional stake of 7.24% in Immunoadoptive Cell Therapy Private Limited (ImmunoACT), an advanced cell and gene therapy company for a cash consideration of Rs.80 Crore. Post the completion of the deal, Laurus Labs' stake in ImmunoACT will increase to 33.86% (on fully diluted basis). This fresh infusion of capital will enable ImmunoACT to fast track the additional supply of the lead candidate HCAR-19 along with the further expansion of the multi-location GMP facilities for manufacturing Chimeric Antigen Receptor T cells (CAR-T cells) treatment to support the growing need for scalable manufacturing. Additionally, some promoters and senior management of Laurus Labs would also acquire in ImmunoACT for a 0.54% stake (before this investment) for approximately Rs. 4 crore at the same price and terms through secondary purchases.

Laurus Labs' earlier investment in ImmunoACT in November 2021 has supported ImmunoACT in successfully creating GMP manufacturing facility along with state of the art R & D facility at Navi Mumbai and currently conducting Phase II study at various hospitals including Tata Memorial Hospital. Phase I data was presented at the American Society of Hematology (ASH) during Nov-2022 that showed a favorable balance of efficacy and toxicity with low-grade cytokine release syndrome.

Commenting on the development, Founder and Chief Executive Officer Dr. Satyanarayana Chava stated *"This investment further strengthens Laurus Labs' commitment to access novel Cell and Gene Therapy technology and enhance its affordability for patients. This investment will further help ImmunoACT to gear up for the manufacture of more treatments. This acquisition is also a step towards our commitment to promote and access novel technologies and making it commercially viable in unmet medical needs of auto immune diseases and oncology. We are looking to invest further in disruptive innovation with a disciplined approach, to enable our strategic partners and customers to bring these promising therapies to patients."*

Commenting on the development, Founder and Chairman of ImmunoACT , Dr.Rahul Purwar stated that -

"With the Laurus first tranche investment, ImmunoACT established GMP facility along with state of the Art R & D facility and sufficiently met funding requirement for conducting on-going Phase II trial. The Current investment will help us to gear up to service more patients across India. We are expecting further collaboration to bring CAR T technologies to the needy Indian Patients at affordable price"

About Laurus | Founded in 2005, Laurus Labs is a research-driven pharmaceutical and biotechnology company with an aim to improve the quality of life for millions of people around the world. Laurus has a global leadership position in select Active Pharmaceutical Ingredients (APIs) including anti-retroviral, oncology drugs (incl High Potent APIs), Cardiovascular, and Gastro therapeutics. Laurus also offer integrated CMO and Contract Development and

Manufacturing Organization (CDMO) services to Global Innovators from Clinical phase drug development to commercial manufacturing.

Laurus is passionate about continuous technological advances for Smart and Green chemistry technologies to drive efficiencies and sustainable manufacturing backed by proven regulatory and quality foundation. Laurus employs 6500+ people, including around 1250+ scientists at more than 11 facilities approved by global agencies USFDA, WHO-Geneva, Japan-PDMA, UK-MHRA, EMA, TGA etc. During FY2023 Laurus generated ₹ 6,041 crore in annual revenue and is listed on the BSE (Bombay Stock Exchange) and the NSE (National Stock Exchange) in India. Laurus' proactive stance to conduct business with utmost Transparency, Integrity and Respect for environment & communities have earned it a place in Governance benchmark, consistently Certified Great Place to Work and Rated "BBB" by leading MSCI ESG Ratings. Corporate Identification No: L24239AP2005PLC047518. For more information visit www.lauruslabs.com

About ImmunoACT and the promoter: Immuno-adoptive Cell Therapy Private Limited (ImmunoACT) is a pioneer in the field of Cell and Gene Therapy. It is in the process of becoming India's first company to introduce the CART therapy for cure of specific types of Blood Cancers which are currently in Clinical Trials. ImmunoACT was founded in 2018 under the aegis of IIT Bombay incubation programme (Society for Innovation and Entrepreneurship) by Dr. Rahul Purwar and a team of eminent scientists. It has an experienced team from the fields of science and business, strong partnership with eminent institutions like Tata Memorial Hospital. Dr Carl June, one of the pioneer in T-Cell therapies for the treatment of Cancer, is a member of its scientific advisory board. Dr Purwar has done his PhD in molecular medicine from Hannover Medical School, Germany and has been a Research Fellow at Harvard Medical School. He also had a stint as scientist at Immunogen Inc., MA, USA prior to dedicating his work life towards research and development of cellular and gene based therapies. His research work is published in highly prestigious journals like Nature Medicine etc. He has been awarded with several awards including Melissa K. Bambino Memorial Award by The Skin Cancer Foundation, USA. For more information visit www.immunoact.com

Laurus Labs Corporate Identification No: L24239AP2005PLC047518

For more information about us, please visit <http://www.lauruslabs.com> or Contact particulars:

Media Relations

Pavan Kumar N

Tel: +91 40 3980 4380

Email: mediarelations@lauruslabs.com

Investor Relations

Vivek Kumar

Tel: +91 40 3980 4366

Email: investorrelations@lauruslabs.com

DISCLAIMER: Certain statements in this document may be forward-looking statements. Such forward-looking statements are subject to certain risks and uncertainties like regulatory changes, local political or economic developments and many other factors that could cause our actual results to differ materially from those contemplated by the relevant forward-looking statements. Laurus Labs Limited (Laurus) will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.

